Skip to Content
Merck
All Photos(1)

Key Documents

549835

Sigma-Aldrich

2,4,6-Tris(dimethylamino)-1,3,5-triazine

96%

Synonym(s):

Altretamine, Hexamethylmelamine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C9H18N6
CAS Number:
Molecular Weight:
210.28
EC Number:
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.22

Quality Level

Assay

96%

mp

171-175 °C (lit.)

functional group

amine

SMILES string

CN(C)c1nc(nc(n1)N(C)C)N(C)C

InChI

1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3

InChI key

UUVWYPNAQBNQJQ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

2,4,6-Tris(dimethylamino)-1,3,5-triazine exhibits antitumor activity.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Triazines and related products. Part 26. Synthesis and chemistry of bicyclic analogues of the antitumour drug 2, 4, 6-tris (dimethylamino)-1, 3, 5-triazine (hexamethylmelamine).
Langdon SP, et al.
Journal of the Chemical Society. Perkin Transactions 1, 993-998 (1984)
Nina Keldsen et al.
Gynecologic oncology, 88(2), 118-122 (2003-02-15)
To evaluate the activity of oral Altretamine in women with epithelial ovarian carcinoma who responded (PR or CR) to first line chemotherapy but relapsed within 6 months. The protocol was later amended to include patients with relapse within 12 months.
R T Zon et al.
Investigational new drugs, 19(3), 229-231 (2001-09-20)
Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were
Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancer.
Mark R Green
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(19), 3112-3113 (2008-07-02)
Yong Soon Kwon et al.
Journal of Korean medical science, 24(4), 679-683 (2009-08-06)
The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between January 1997 and November 2006 and in documented clinical complete

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service